Marinus Pharmaceuticals (MRNS) Filings

8-K

MRNS Marinus Pharmaceuticals Inc

30 May 23

The European Commission decision is expected within 67 days of the CHMP opinion

4:05pm

8-K

MRNS Marinus Pharmaceuticals Inc

30 May 23

Submission of Matters to a Vote of Security Holders

8:45am

4

Noonberg Sarah B.

17 May 23

MARINUS PHARMACEUTICALS / Sarah B. Noonberg ownership change

9:08pm

3

Noonberg Sarah B.

17 May 23

MARINUS PHARMACEUTICALS / Sarah B. Noonberg ownership change

9:02pm

8-K

MRNS Marinus Pharmaceuticals Inc

17 May 23

Departure of Directors or Certain Officers

4:02pm

8-K

MRNS Marinus Pharmaceuticals Inc

11 May 23

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

7:03am

4

Marvin Johnson

19 Apr 23

MARINUS PHARMACEUTICALS / Marvin Johnson ownership change

4:03pm

3

Marvin Johnson

19 Apr 23

MARINUS PHARMACEUTICALS / Marvin Johnson ownership change

4:02pm

8-K

MRNS Marinus Pharmaceuticals Inc

18 Apr 23

Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors

7:05am

EFFECT

MRNS Marinus Pharmaceuticals Inc

12 Apr 23

Notice of effectiveness

12:15am

DEFA14A

MRNS Marinus Pharmaceuticals Inc

11 Apr 23

Additional proxy soliciting materials

6:04am

CORRESP

MRNS Marinus Pharmaceuticals Inc

11 Apr 23

Correspondence with SEC

12:00am

UPLOAD

MRNS Marinus Pharmaceuticals Inc

5 Apr 23

Letter from SEC

12:00am

8-K

MRNS Marinus Pharmaceuticals Inc

31 Mar 23

Entry into a Material Definitive Agreement

5:12pm

8-K

MRNS Marinus Pharmaceuticals Inc

22 Mar 23

Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome

6:09pm

8-K

MRNS Marinus Pharmaceuticals Inc

10 Mar 23

Other Events

4:23pm